Immunotherapy before or after surgery — how the order is actually decided

There is no single correct order. Immunotherapy is given before surgery, after surgery, or both. The sequence follows the cancer type, the stage, the biomarker result on your biopsy, and whether an approved indication exists for that order. It is set by your treating team after tumour board review.

Both orders are established approaches with different purposes. Given before surgery, immunotherapy acts on a tumour that is still in place and measurable. Given after surgery, it is aimed at cancer cells that no scan can see. Neither one is a fallback for the other.

This is a genuine clinical fork, and patients are rarely walked through it. Most people are told what the plan is, not why that order was chosen over the alternative. You are entitled to ask, and the reasoning should be explainable to you in plain language.

Nothing on this page decides your sequence. Every sequencing decision belongs to the oncologist and surgeon treating you, working from your scans, your biopsy report, and your fitness for each step.

Neither column is a recommendation. Which one applies to you depends on findings your treating team already has and this page does not. Immunotherapy at CION is given as day care; response-assessment imaging is coordinated at partner imaging centres.

Yes, by design, when it is given first. Surgery is scheduled after a fixed, planned course of cycles rather than being pushed back week by week. Imaging is used along the way. It is a monitored, time-limited delay, agreed with your surgeon before treatment starts.

The delay is set in advance, and the surgical team is part of setting it. If immunotherapy is given after surgery instead, the operation is not delayed at all — the sequence begins with the operation, and treatment follows once you have recovered enough and the pathology report is back.

Side effects can still move a date. Immune-related reactions occasionally require treatment to pause, and a pause can shift a planned operation. Report any new symptom to your treating team promptly, and never stop, delay, or restart treatment on your own to protect a surgical date.

• Cancer type and approved indication — only some cancers have an approved sequence that puts immunotherapy first. Where none exists, surgery leads.
• Stage and operability today — a borderline operable tumour may be treated first to make the operation more feasible. A clearly operable one often is not.
• The biomarker result on your biopsy — several sequences depend on a specific marker result from the diagnostic tissue before they can be used at all.
• How urgent the surgery is — bleeding, obstruction, or a rapidly growing tumour push the operation to the front of the queue, whatever else is true.
• Your fitness and other conditions — an autoimmune condition, steroids taken for another illness, or organ function can make one order safer for you specifically.
• What the tumour board agrees — medical oncology, surgical oncology, and radiology decide the order together, and it is recorded in your treatment plan.

None of these decides anything on its own. Ask your treating team which factor was decisive in your case — it is a fair question, and the answer should be specific to your reports rather than general. If you already take steroids for another condition, raise it early: it is one of the more common reasons a sequence gets reconsidered, and it is covered in immunotherapy and steroids taken for another condition.

Yes. A planned sequence is reviewed as it goes, not fixed forever. Scan findings, side effects, or how well you tolerate treatment can move surgery earlier or later, or change what follows it. Any change goes back through your treating team, rather than being decided at one appointment.

If immunotherapy is given first and the tumour does not shrink as hoped, surgery generally still goes ahead. The operation was never conditional on a perfect response. Your surgeon reassesses with fresh imaging and may adjust the surgical approach, but the intention to operate does not disappear.

Gaps between different treatments are part of the same planning conversation. If chemotherapy is also in your plan, the spacing between it and immunotherapy is set deliberately, not left to chance — see how long after chemotherapy immunotherapy can start. What happens once a planned course ends is a separate question again, covered in what comes after immunotherapy.

If your surgery and your immunotherapy are happening at different hospitals, ask for the sequence and the dates in writing. Both teams should be working from the same plan, and a written sequence is the simplest way to make sure they are.

• How Long After Chemotherapy Can Immunotherapy Start? — useful if chemotherapy is also in your plan and you are trying to work out where surgery fits between the two.
• Immunotherapy and Steroids Taken for Another Condition — read this before your sequencing discussion if you are already on steroids for an unrelated illness.
• What Comes After Immunotherapy? Planning the Next Line — for the question that follows this one: what the plan looks like once a planned course finishes.
• Immunotherapy at CION Cancer Clinics — how CION supports patients through sequencing decisions, from biopsy review and tumour board to day-care treatment and surgical coordination.

This page is for general information and does not replace a consultation. It describes drug classes and treatment sequences in general terms, drawn from NCCN, ASCO, and ESMO patient-education guidance. It names no medicine and no regimen, makes no prediction of outcome for any individual patient, and contains no survival statistic of any kind. Your sequence is a decision for the oncologist and surgeon treating you.

Asking about the order is not questioning your doctor

Wanting to know why treatment comes before the operation, or after it, is how informed patients make this decision. Our team walks through your specific scans and reports, and explains the sequence honestly.